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Editorial EPO for stroke therapy - Is there a future for further 
clinical development?
Jens Minnerup*1, Heike Wersching2 and Wolf-Rüdiger Schäbitz3
Editorial
The recently published double-blind, placebo-controlled,
randomized phase II/III German Multicenter EPO Stroke
Trial was conducted to evaluate the efficacy and safety of
Erythropoietin (EPO) in stroke patients [1]. Of the 522
patients enrolled in this trial 460 were treated as planned
(per-protocol population) with either EPO or placebo
within 6 hours of symptom onset. The primary endpoint,
change in Barthel Index on day 90, and all secondary out-
comes failed to show any benefit of EPO. Moreover, an
increased rate of intracerebral haemorrhages was
observed after EPO treatment, resulting in an increased
mortality in the EPO group. This effect was pronounced
in patients who received EPO in addition to rt-PA.
In this Editorial we discuss potential reasons for the
negative results of the German Multicenter EPO Stroke
Trial, which contrasted the findings of a clinical pilot trial
and several preclinical studies that showed beneficial
effects of EPO [2,3]. Altogether we want to reflect on four
major issues: 1. The overestimated efficacy of EPO in pre-
clinical studies due to neglected quality characteristics in
animal experiments. 2. An underpowering caused by the
study design of the German Multicenter EPO Stroke
Trial. 3. Unexpected side effects of EPO. 4. The future for
a further development of EPO as a stroke drug.
So far EPO and EPO analogues were widely tested in
animal stroke models [3]. In a meta-analysis of preclinical
studies we analyzed the overall efficacy in focal cerebral
ischemia. EPO and EPO analogues reduced infarct vol-
umes by 32% and improved neurobehavioral deficits by
37% to 38%. However, Philip et al. recently showed that
the quality of preclinical EPO studies as measured by a
STAIR derived quality score was relatively low [4]. This is
a crucial point because disregarding basic quality stan-
dards may cause an overestimation of a drug's efficacy in
animal studies [5,6]. Indeed, this might be the case in
experimental EPO studies. When animals were random-
ized to EPO treatment or placebo the efficacy was lower
compared to studies in which randomization was not
reported [7]. The way in which the outcome was assessed
was identified as a further potential source of bias. When
comparing studies that blindly assessed neurobehavioral
deficits to studies with an unblinded assessment of out-
come the latter reported a significantly higher efficacy of
EPO [7].
The study design of the German Multicenter Stroke
Trial is another potential reason for the failure to repli-
cate the positive findings of prior preclinical and clinical
studies. A particularly critical point is the allowed combi-
nation of rt-PA and EPO. This combination of treatments
was neither investigated in animal models nor in the clin-
ical pilot trial. Therefore adverse interactions of these two
drugs as suggested by the increased rate of intracerebral
haemorrhages in the German Multicenter Stroke Trial
were unpredictable. A preceding investigation of EPO-rt-
PA interactions could have had prevented a combination
therapy in the clinical trial. In fact, a present mouse
stroke study by Zechariah et al. showed that a combina-
tion of EPO and rt-PA induces blood-brain barrier per-
meability and extracellular matrix disaggregation [8].
However, it is uncertain whether the results of a single
animal study based on surrogate markers would have
influenced further clinical development of EPO, particu-
larly in combination with rt-PA. When considering that
an increasing number of stroke patients is treated with rt-
PA within a therapeutical time window also adequate for
neuroprotective therapies, the importance of thoroughly
testing combination therapies in animal studies becomes
evident [9]. This particularly includes investigations of
whether the drugs interfere regarding their efficacy and
safety. In addition, the allowed combination of EPO and
rt-PA is critical for the issue of study power. Altogether, it
is rather difficult to measure a beneficial effect on top of a
highly effective therapy such as thrombolysis. The inclu-
sion criteria also might have reduced the power: Patients
w i t h  p r e - e x i s t i n g  d i s a b i l i t y  w e r e  i n c l u d e d  i n  t h e  s t u d y
making it difficult to measure treatment-related differ-
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ences on the primary outcome Barthel Index or on sec-
ondary outcomes such as the modified Rankin Scale.
However, the pre-stroke Barthel Index and the pre-stroke
modified Rankin Scale were not reported in the manu-
script.
The negative findings of the German Multicenter EPO
Stroke Trial could be a result of previously unknown side
effects of EPO. So far, it was known that EPO increases
the risk for myocardial infarction and composite end-
points of death and cardiovascular events in patients with
anaemia due to chronic kidney disease [10]. In addition,
some years ago EPO was shown to enhance tumor pro-
gression and shorten survival in patients with some types
of cancer [11]. Results of the more recent TREAT study
suggest an intrinsic stroke-inducing capacity of EPO. In
this study patients with diabetes, chronic kidney disease,
and anaemia were randomly assigned to receive darbepo-
etin alfa or placebo [12]. Surprisingly, a significant higher
number of strokes occurred in the darbepoetin alfa
treated group compared to the placebo group. Unfortu-
nately, it was not reported whether those strokes were
ischemic or hemorrhagic [13].
The question arises what the disappointing results of
the recent EPO trial mean for a future clinical develop-
ment of the drug. One might consider that a further clini-
cal stroke trial which excludes patients treated with rt-PA
might show beneficial effects of EPO. Results of the Ger-
man Multicenter EPO Stroke Trial, however, do not
strongly support this assumption. In a subgroup analysis
of non-rt-PA group none of the primary endpoints dif-
fered significantly between EPO and placebo treated
patients. Only one secondary outcome measure, the delta
NIHSS (NIHSS Day 1 minus Day 90) [1], revealed a better
outcome after EPO treatment. In non-rt-PA treated
patients there was even a tendency toward a higher death
rate in the EPO group. The authors point out that this
might be explained by the higher stroke severity of the
dead patients on inclusion. Overall, the potential side
effects of EPO will presumably prevent the conduction of
further clinical stroke trials. However, non-haematopoi-
etic EPO analogues remain as a therapeutic option for
stroke, since the adverse effects of EPO were assumed to
be mainly caused by its erythropoiesis stimulating effects.
In a meta-analysis of preclinical studies we showed that
non-hematopoietic EPO analogues are at least as effec-
tive as hematopoietic EPO-analogues [3]. The reason
therefore might be EPO's mode of action in ischemic
stroke, which is assumed to be based on a direct effect on
neurons rather than on an increased hematopoiesis (for
review see [14]). It was shown, that EPO receptors are
expressed in the brain and that the neuronal EPO recep-
tors which are distinct from those expressed by erythro-
poid precursors are stimulated by non-hematopoietic
EPO analogues. Evidence regarding the safety of non-
hematopoietic EPO analogues in stroke patients is
expected in the near future since one clinical pilot trial of
Carbamylated EPO in stroke patients was recently com-
pleted and another pilot trial has already started (http://
www.clinicaltrials.gov/; NCT00756249 and
NCT00870844). The future of non-hematopoietic EPO
analogues for a further clinical development for stroke
therapy will depend on the safety results of these trials.
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